Clinical Insight 6 Min Read
GLP-1 Weight-Loss Pills: Everything You Need To Know
Graham Phillips
FRPharmS • Founder
For years, the GLP-1 weight-loss medicines including Wegovy® and Mounjaro®, were available only as injections. That changed in 2026. On 11 June, the MHRA (the UK Medicines Licensing Authority) authorised the first GLP-1 tablet specifically weight management: a once-daily Wegovy tablet containing semaglutide. Then, on 10 August, the UK became the first country in Europe to authorise Foundayo® (orforglipron), a second once-daily GLP-1 weight-loss tablet.
This is important because now have two oral alternatives to weekly injections. But tablets are not inherently more effective, easier to tolerate or more convenient. So how do Wegovy tablets and Foundayo compare with each other? And with Wegovy and Mounjaro injections?
(The relevant official announcements are here: Wegovy tablet authorisation and here Foundayo authorisation)
What Exactly are GLP-1 Weight-Loss Pills?
GLP-1 medicines mimic a natural hormone produced in the gut after eating. They help reduce appetite, increase feelings of fullness and slow stomach emptying, making it easier for many people to eat less without feeling constantly hungry. These medicines have transformed obesity treatment over the past few years, helping many people achieve significant weight loss where previous approaches had failed. Until recently, however, GLP-1 drugs could only be delivered by injection because the medication was easily broken down in the stomach before it could be absorbed into the bloodstream. The newly approved Wegovy tablet overcomes this challenge and provides the first oral GLP-1 medicine licensed specifically for weight management in the UK.
If you’d like to understand more about how these medications work, read our article: How GLP-1 Drugs Work for Weight Loss
Wegovy Tablets vs. Foundayo: What Is the Difference?
Wegovy tablets contain semaglutide, the same medicine used in Wegovy injections. Treatment starts at 1.5 mg once daily and is gradually increased through 4 mg and 9 mg to a maintenance dose of 25 mg.
Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly. Treatment begins at 0.8 mg once daily and can be increased gradually through 2.5 mg, 5.5 mg, 9 mg and 14.5 mg to a maximum of 17.2 mg, according to response and tolerability.
Foundayo is not Mounjaro in tablet form. Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors. Foundayo activates the GLP-1 receptor. (NB There is currently no licensed oral tirzepatide or oral Mounjaro product in the UK.)
( The doses are confirmed in the Wegovy tablet SmPC and Foundayo SmPC.
GLP-1 Weight-Loss Pills vs Injections: Which Works Best?
That depends on what we mean by “best”. Average weight loss matters, but so do side effects, convenience, cost, and whether the treatment can be sustained.
In OASIS 4, people taking the licensed 25 mg Wegovy tablet lost an average of 13.6% of their starting weight after 64 weeks, compared with 2.2% on placebo. In ATTAIN-1, those receiving the highest Foundayo dose lost an average of 11.2% after 72 weeks, compared with 2.1% on placebo.
For context, injectable Wegovy 2.4 mg has generally produced average weight loss of around 15%, while the newer 7.2 mg dose produced 18.7% in STEP UP. Across the licensed Mounjaro maintenance doses, average weight loss in SURMOUNT-1 ranged from approximately 15% to 21%.
These figures come from different trials and should not be treated as a league table. There has been no head-to-head randomised trial comparing Wegovy tablets directly with Foundayo, but our overall view is that the injections are more potent, that Mounjaro generally beats Wegovy and that Wegovy tablets are more potent than Foundayo. But we repeat: Average weight loss matters, but so do side effects, convenience, cost, and whether the treatment can be sustained.
(Sources: OASIS 4 oral semaglutide trial, ATTAIN-1 orforglipron trial, STEP UP 7.2 mg semaglutide trial and SURMOUNT-1 tirzepatide trial.)
A Tablet Isn’t Necessarily Easier
Many people assume that swallowing a tablet must be simpler than using an injection pen, but the answer depends on which tablet.
Wegovy tablets must be taken after fasting for at least eight hours. The tablet should be swallowed whole with no more than 120 mL of water, followed by a wait of at least 30 minutes before eating, drinking or taking other oral medicines. Following these instructions is important because oral semaglutide has relatively low and variable absorption.
Foundayo is simpler in this respect. It can be taken once daily at any time, without food or water restrictions.
For some people, a daily tablet will be preferable. For others, one weekly injection may still be easier than remembering a tablet every day, particularly when that tablet requires a strict morning routine.
The Side Effects Are Similar
Changing from an injection to a tablet does not eliminate GLP-1 side effects. Nausea, vomiting, constipation, diarrhoea, indigestion and abdominal discomfort remain common because they result principally the way the medicine work irrespective the route of administration.
Put simply: Oral or Injection? Same medicine – same side-effects!
In OASIS 4, gastrointestinal adverse events were reported by 74.0% of participants receiving Wegovy tablets, compared with 42.2% receiving placebo. In Foundayo’s weight-management trials, gastrointestinal disorders affected approximately 60–69% of participants, depending on dose, compared with 36% receiving placebo.
A tablet may be easier to administer, but it is not necessarily easier to tolerate.
Important Safety Warnings
Vomiting or diarrhoea can cause dehydration and deterioration in kidney function. Gallstones, severe constipation and delayed gastric emptying are also recognised concerns.
Seek urgent medical attention for severe, persistent abdominal pain, particularly pain radiating to the back, with or without nausea or vomiting. This may indicate acute pancreatitis.
In January 2026, the MHRA strengthened the warnings across the GLP-1 class following rare reports of necrotising and fatal pancreatitis. Always tell the surgical or anaesthetic team that you take a GLP-1 medicine before general anaesthesia or deep sedation.
Foundayo may also reduce the effectiveness of oral hormonal contraception. Its product information advises adding a barrier method or changing to a non-oral contraceptive for 30 days after starting treatment and for 30 days after every dose increase.
Source: MHRA strengthened pancreatitis warning, 29 January 2026.
The Bigger Question Nobody Is Asking
But the most important question is not simply whether a GLP-1 arrives by pen, pill or even carrier pigeon!! It is what happens when treatment stops.
Weight regain after stopping GLP-1 treatment is common. In the STEP 1 extension, participants regained on average around two-thirds of the weight they had just 12-month after stopping Wegovy (semaglutide) This does not prove that every person must remain on medication for life, but it does show that medication-induced appetite control is not the same as permanently changing the food environment and all the pressures that caused the weight gain in the first place
Medication can reduce hunger and make weight loss easier, but it does not automatically improve food quality, protect muscle, establish an exercise routine or create a workable maintenance plan.
This is why we encourage people to think about their exit strategy before they start treatment, not after they stop.
For a deeper discussion of this issue, read: Coming Off GLP-1s: What Happens Next? , The Science Behind Lasting Weight Loss and also Foundayo (Orforglipron): Is It Really a “Treatment for Life”?
Looking Beyond Weight Loss
One of the biggest mistakes people make is viewing obesity purely as a weight problem. In reality, excess weight is often a symptom of deeper metabolic issues such as insulin resistance, poor sleep, stress, sedentary lifestyles and diets dominated by ultra-processed foods. This is why we focus so heavily on metabolic health rather than simply chasing lower numbers on the scales.
If this concept is new to you, these articles are a great place to start:
Metabolic Health: The Unsung Hero of Healthy Longevity
What Is Metabolic Syndrome?
Understanding and addressing these underlying drivers may be just as important as any medication you take.
A Different Way Forward
At ProLongevity Essentials, we believe medication can be a useful tool, but it should never be the entire strategy.Whether you’re considering injections, tablets or no medication at all, sustainable results depend on understanding your metabolism and building habits that support long-term health. For many people, that means improving sleep, increasing protein intake, building muscle through resistance exercise, reducing ultra-processed foods and learning how to manage food noise without becoming dependent on medication forever. If you’re looking for an alternative perspective, read: How to Permanently Lose Weight Without Using a GLP-1 Drug
You may also find our guide to Continuous Glucose Monitoring helpful
The Bottom Line
The arrival of Wegovy tablets and Foundayo is a genuine development in UK obesity treatment. People who prefer not to inject now have two good oral options.
Separate trials suggest that Wegovy tablets may produce somewhat greater average weight loss, but they require strict fasting and water instructions. Foundayo appears slightly less effective on average but is considerably simpler to take. Neither tablet has been shown to be superior in a direct head-to-head trial.
Tablets remove the needle, but they do not remove GLP-1 side effects, the need for careful prescribing or the risk of weight regain when treatment ends.
The fundamentals therefore remain unchanged: protect muscle, prioritise nutrition, improve metabolic health and use the opportunity created by reduced hunger to build habits that can endure.
The future of weight-loss medication may increasingly include tablets. But the future of long-term health still depends on what happens beyond the prescription.
Need help applying this to your own health?
About Graham Phillips
Graham Phillips is a registered pharmacist (FRPharmS) with over 35 years of experience. Frustrated by “pill for every ill” medicine, he founded ProLongevity to help people reverse chronic disease and lose weight through precision lifestyle medicine.
